DrugPatentWatch Database Preview
Ibritumomab tiuxetan - Biologic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for ibritumomab tiuxetan
| Tradenames: | 1 |
| Patents: | 142 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 2 |
| Recent Clinical Trials: | See clinical trials for ibritumomab tiuxetan |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ibritumomab tiuxetan |
Recent Clinical Trials for ibritumomab tiuxetan
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 3 |
| University of California, Davis | Phase 2 |
| Spectrum Pharmaceuticals, Inc | Phase 3 |
Recent Litigation for ibritumomab tiuxetan
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Biogen Idec, Inc. v. Glaxosmithkline LLC | 2010-03-24 |
| IDERA PHARMACEUTICALS, INC. v. KAPPOS | 2010-01-29 |
| Genentech, Inc. v. Sanofi-Aventis Deutschland GMBH | 2008-10-27 |
Company Disclosures: US Patents for ibritumomab tiuxetan
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Idec Pharmaceuticals Corporation (San Diego, CA) | 2015-04-07 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceuticals Corporation (San Diego, CA) | 2015-07-07 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | 2015-12-01 | RX | Orphan | company | |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceuticals Corporation (San Diego, CA) | 2039-03-29 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceutical Corporation (San Diego, CA) | 2019-06-04 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceuticals Corporation (San Diego, CA) | 2021-01-27 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Biogen IDEC Inc. (Cambridge, MA) | 2019-03-01 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for ibritumomab tiuxetan
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corpoartion (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Human Genome Sciences, Inc. (Rockville, MD) The Regents of the University of Michigan (Ann Arbor, MI) | 2017-01-28 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Momenta Pharmaceuticals, Inc. (Cambridge, MA) | 2023-10-01 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Idera Pharmaceuticals, Inc. (Cambridge, MA) | 2023-05-16 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Bayer Schering Pharma Aktiengesellschaft (Berlin, DE) | 2024-09-06 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ibritumomab tiuxetan
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2000149 | Start Trial |
| Australia | 2008300497 | Start Trial |
| Eurasian Patent Organization | 032434 | Start Trial |
| South Africa | 200501851 | Start Trial |
| South Korea | 101363658 | Start Trial |
| European Patent Office | 2163643 | Start Trial |
| Japan | 5214252 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ibritumomab tiuxetan
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 620 | Luxembourg | Start Trial | 91620, EXPIRES: 20181112 |
| 00424 | Netherlands | Start Trial | PORDUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127 |
| 2016000049 | Germany | Start Trial | PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621 |
| C0018 | France | Start Trial | PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116 |
| 0156 | Netherlands | Start Trial | PRODUCT NAME: IBRITUMOMAB; REGISTRATION NO/DATE: EU/1/03/264/001 20040116 |
| C/GB04/025 | United Kingdom | Start Trial | PRODUCT NAME: IBRITUMOMAB COMPRISING A CHELATING AGENT FOR YTTRIUM (90); REGISTERED: UK EU/1/03/264/001 20040116 |
| /2004 | Austria | Start Trial | PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
